Heidi Juntunen1,2, Heidi Taipale1,2,3, Antti Tanskanen3,4, Anna-Maija Tolppanen1,2, Jari Tiihonen3,4, Sirpa Hartikainen1,2, Miia Tiihonen5,6. 1. Kuopio Research Centre of Geriatric Care, University of Eastern Finland, P.O.B 1627, -70211, Kuopio, FI, Finland. 2. School of Pharmacy, University of Eastern Finland, P.O.B 1627, -70211, Kuopio, FI, Finland. 3. Department of Clinical Neuroscience, Karolinska Institutet, -171 77, Stockholm, SE, Sweden. 4. Department of Forensic Psychiatry, Niuvanniemi Hospital, University of Eastern Finland, Niuvankuja 65, FI-70240, Kuopio, Finland. 5. Kuopio Research Centre of Geriatric Care, University of Eastern Finland, P.O.B 1627, -70211, Kuopio, FI, Finland. miia.tiihonen@uef.fi. 6. School of Pharmacy, University of Eastern Finland, P.O.B 1627, -70211, Kuopio, FI, Finland. miia.tiihonen@uef.fi.
Abstract
PURPOSE: The aim of this study is to determine the prevalence of use and long-term use (≥180 days) of proton pump inhibitors (PPIs) and associated factors among community-dwellers with and without Alzheimer's disease (AD). METHODS: MEDALZ cohort encompassed all persons who received a verified diagnosis of AD in Finland during the years 2005-2011 and their age-, sex-, and region of residence-matched comparison persons, including 69,353 persons with and 69,353 persons without AD. Data was derived from several Finnish administrative registers. A mathematical modelling method, PRE2DUP, was used for converting dispensing data to drug use periods (when regular PPI use started and ended). Morbid conditions and concomitant drugs associated with use and long-term use of PPIs were assessed with logistic regression models. RESULTS: Use of PPIs was more common among comparison persons than persons with AD (39.0 and 35.8%, respectively, p < 0.001), whereas long-term use of PPIs was more frequent among persons with than without AD (20.3 and 17.9%, respectively, p < 0.001). Factors related to long-term use of PPIs were female sex, history of gastrointestinal bleedings, AD, rheumatoid arthritis, cardiovascular disease, asthma/COPD and use of bisphosphonates, SSRIs and antithrombotic agents. Median follow-up time was 2.6 years among persons with AD and 3.5 years among persons without AD. Median duration of the first long-term PPI use was similar in both groups (1.4 years). CONCLUSION: Long-term use of PPIs was common among persons with and without AD. Due to possible adverse events associated with the long-term use of PPIs, need for PPIs should be assessed regularly.
PURPOSE: The aim of this study is to determine the prevalence of use and long-term use (≥180 days) of proton pump inhibitors (PPIs) and associated factors among community-dwellers with and without Alzheimer's disease (AD). METHODS: MEDALZ cohort encompassed all persons who received a verified diagnosis of AD in Finland during the years 2005-2011 and their age-, sex-, and region of residence-matched comparison persons, including 69,353 persons with and 69,353 persons without AD. Data was derived from several Finnish administrative registers. A mathematical modelling method, PRE2DUP, was used for converting dispensing data to drug use periods (when regular PPI use started and ended). Morbid conditions and concomitant drugs associated with use and long-term use of PPIs were assessed with logistic regression models. RESULTS: Use of PPIs was more common among comparison persons than persons with AD (39.0 and 35.8%, respectively, p < 0.001), whereas long-term use of PPIs was more frequent among persons with than without AD (20.3 and 17.9%, respectively, p < 0.001). Factors related to long-term use of PPIs were female sex, history of gastrointestinal bleedings, AD, rheumatoid arthritis, cardiovascular disease, asthma/COPD and use of bisphosphonates, SSRIs and antithrombotic agents. Median follow-up time was 2.6 years among persons with AD and 3.5 years among persons without AD. Median duration of the first long-term PPI use was similar in both groups (1.4 years). CONCLUSION: Long-term use of PPIs was common among persons with and without AD. Due to possible adverse events associated with the long-term use of PPIs, need for PPIs should be assessed regularly.
Authors: P F Haastrup; M S Paulsen; R D Christensen; J Søndergaard; J M Hansen; D E Jarbøl Journal: Aliment Pharmacol Ther Date: 2016-05-03 Impact factor: 8.171
Authors: Anna Papazoglou; Muhammad I Arshaad; Christina Henseler; Johanna Daubner; Karl Broich; Britta Haenisch; Marco Weiergräber Journal: Curr Alzheimer Res Date: 2021 Impact factor: 3.498